Value proposition

Seagen is now part of Pfizer! Together with our Pfizer colleagues, we will continue our mission of bringing life-saving treatments to people living with cancer.

Our scientific leadership and world-leading antibody-drug conjugate (ADC) technology combined with the scale and strength of Pfizer's capabilities and expertise, will help position Pfizer at the forefront of innovation in cancer care.

We are so proud of our employees for the work that has been done over the past 25 years to positively impact the cancer community.

Check out the announcement https://lnkd.in/dfq7V-tw to join us in our excitement for the future.

Seagen social media accounts, including this page, will no longer be active or monitored. Please follow Pfizer https://www.linkedin.com/company/pfizer/ for new content!

Antibody-Drug Conjugates, Conjugation Chemistry, Monoclonal antibody-based therapies for cancer, Cancer drug development, Drug development, Blood cancers, Bladder cancer, Hodgkin lymphoma, and Non-Hodgkin lymphoma